N-Acetyl cysteine averted liver transplantation in a patient with liver failure caused by erythropoietic protoporphyria

Liver Transplantation

Volumn 15, Issue 3, 2009, Pages 352-354

  Šperl, Jan ^a   Procházková, Jana ^c   Martásek, Pavel ^c   Subhanová, Iva ^c   Fraňknová, Sonňa ^a   Trunec̃ka, Pavel ^a   Jirsa, Milan ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Institute for Clinical and Expiremental Medicine   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA CAROTENE; BILIRUBIN; ERYTHROCYTE PROTOPORPHYRIN; GAMMA GLUTAMYLTRANSFERASE; PROTOPORPHYRIN; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHOLESTASIS; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONTINUOUS INFUSION; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATOMEGALY; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LETTER; LIVER BIOPSY; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; MALE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTHROMBIN TIME;

ACETYLCYSTEINE; ADULT; EXONS; FERROCHELATASE; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTOPORPHYRIA, ERYTHROPOIETIC;

EID: 67649217804     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21669     Document Type: Letter

References (8)

1. Eefsen M, Rasmussen A, Wulf HC, Brock A, Hansen BA. Erythropoietic protoporphyria and pretransplantation treatment with nonbiological liver assist devices. Liver Transpl 2007;13:655-657.
2. Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. Gut 2007;56:1009-1018.
3. Aitio ML. N-acetylcysteine - passe-partout or much ado about nothing? Br J Clin Pharmacol 2006;61:5-15.
4. Gouya L, Puy H, Robreau AM, Bourgeois M, Lamoril J, Da Silva V, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wild type FECH. Nat Genet 2002;30:27-28.
5. Cox TM, Alexander GJ, Sarkany RP. Protoporphyria. Semin Liver Dis 1998;18:85-93.
6. Gross JB Jr, Reichen J, Zeltner TB, Zimmermann A. The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass. Hepatology 1987;7:457-463.
7. Meerman L, Koopen NR, Bloks V, Van Goor H, Havinga R, Wolthers BG, et al. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 1999;117:696-705.
8. Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl 2008;14:25-30.